IGHG1 and cancer: By constructing siRNA that targets the IGHG1 (immunoglobulin heavy constant gamma 1) gene, we performed cancer-IgG knockdown within PC9 and H292 cells; siRNA2 presented to be more efficient (Figure 2C).